Compare Abbott Laboratories (ABT) vs Newmont Corporation (NEM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Newmont Corporation — how do they compare? Abbott Laboratories trades at $96.05 (market cap $166.94B), while Newmont Corporation trades at $92.38 (market cap $101.48B). The key difference: Abbott Laboratories is the larger of the two by market cap, and Abbott Laboratories pays the higher dividend (2.63%). Which is the better fit depends on your goals.
| ABT | NEM | |
|---|---|---|
Market Cap | $166.94B | $101.48B |
Sector | Health | Basic Materials |
52-Week High | $136.62 | $131.95 |
52-Week Low | $82.57 | $57.35 |
Enterprise Value | $193.69B | $98.23B |
Dividend Yield | 2.63% | 1.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
Newmont Corporation (NEM) trades at $95.06, down 2.04% over 24 hours amid a bearish technical signal. The stock shows strong fundamentals with Q1 2026 EPS beating estimates at $2.90 versus $2.07 expected, revenue growth to $22.67 billion in 2025, and robust cash flow of $10.33 billion from operations. Analyst consensus is bullish with a $144.00 price target and 75% buy ratings, though recent gold price volatility has pressured shares.
The outlook remains positive due to low valuation multiples (P/E 12.74, EV/EBITDA 6.27) and record free cash flow, but risks include gold market fluctuations and execution of expansion projects. The stock presents a value opportunity for long-term investors, supported by a strong balance sheet and dividend payments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Newmont Corporation
Newmont Corp is primarily a gold producer with operations and/or assets in the United States, Canada, Mexico, Dominican Republic, Peru, Suriname, Argentina, Chile, Australia, and Ghana. It is also engaged in the production of copper, silver, lead and zinc. The company's operations are organized in five geographic regions: North America, South America, Australia, Africa and Nevada.
Read more on NEM →
